CALL - SPRINTER OPEN END - AMGEN | Delayed Deutsche Boerse AG 12:53:28 02/07/2024 BST | ||
| 8.02 EUR | -0.50% |
|
| Current month | -2.42% | ||
| 1 month | +7.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 02/07/24 | 8.02 | -0.50% |
| 01/07/24 | 8.06 | -2.42% |
| 28/06/24 | 8.26 | +0.24% |
| 27/06/24 | 8.24 | -1.32% |
| 26/06/24 | 8.35 | -6.18% |
Delayed Quote Deutsche Boerse AG
Last update July 02, 2024 at 12:53 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VV16X2 |
| ISIN | DE000VV16X29 |
| Date issued | 06/05/2022 |
| Strike | 225.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.99 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.9 € |
|---|---|
| Lowest since issue | 0.42 € |
| Spread | 0.02 € |
| Spread % | 0.26% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
311
USD
Average target price
316.4
USD
Spread / Average Target
+1.75%
- Stock Market
- Certificates
- Certificat
